Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy
Abstract
Purpose:
Laboratory and epidemiological studies suggest that high circulating insulin-like growth factor (IGF)-1 and low IGF binding protein-3 are associated with increased prostate cancer risk. However, the usefulness of serum IGF-1 or IGF binding protein-3 for predicting pathology results in men undergoing prostate biopsy is unclear. We examined the relationships of serum IGF-1, IGF binding protein-3 and the results of prostate biopsy.
Materials and Methods:
A total of 652 consecutive patients with elevated serum prostate specific antigen (PSA) or abnormal digital rectal examination who were referred for transrectal ultrasound sextant prostate needle biopsy underwent blood sampling before biopsy. PSA, free PSA, IGF-1 and IGF binding protein-3 were measured. There were 244 men (37.4%) with cancer and 408 controls with benign conditions.
Results:
Mean IGF-1 plus or minus SD in the cancer and control groups was 176.1 ± 58.3 and 178.7 ± 54.7 ng./ml., respectively (p = 0.57). Mean IGF binding protein-3 in the cancer and control groups was 2,724 ± 647 and 2,673 ± 589 ng./ml., respectively (p = 0.3). Adjustment for age and PSA showed significantly lower IGF-1 in cancer cases, while IGF binding protein-3 was not significant. ROC values were significantly higher for free-to-total PSA and PSA than for crude and age adjusted IGF-1 and IGF binding protein-3.
Conclusions:
Our data indicate that serum IGF-1 or IGF binding protein-3 does not predict the results of prostate biopsy in men with elevated PSA or abnormal digital rectal examination. This finding implies that while there is evidence that the IGF-1 level is a risk factor for prostate cancer, neither IGF-1 nor IGF binding protein-3 can be used as a tumor marker for this disease.
References
- 1 : Insulin-like growth factor and prostate cancer. Epidemiol Rev2001; 23: 59. Crossref, Medline, Google Scholar
- 2 : Prostate-specific antigen (PSA) is an insulin-like growth factor-binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab1992; 75: 1046. Medline, Google Scholar
- 3 : Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science1998; 279: 563. Crossref, Medline, Google Scholar
- 4 : Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer1997; 76: 1115. Crossref, Medline, Google Scholar
- 5 : Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst1998; 90: 911. Crossref, Medline, Google Scholar
- 6 : Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst2000; 92: 1910. Crossref, Medline, Google Scholar
- 7 : Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab2000; 85: 4258. Crossref, Medline, Google Scholar
- 8 : Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab1993; 77: 229. Medline, Google Scholar
- 9 : Insulin-like growth factor and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev2001; 10: 421. Medline, Google Scholar
- 10 : Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab2001; 86: 694. Crossref, Medline, Google Scholar
- 11 : IGF-1 and prostate cancer. Science1998; 282: 199. Crossref, Google Scholar
- 12 : Insulin-like growth factor-1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology1999; 54: 603. Crossref, Medline, Google Scholar
- 13 : The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int2000; 85: 125. Crossref, Medline, Google Scholar
- 14 : Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol1997; 46: 333. Crossref, Medline, Google Scholar
- 15 : Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int1999; 83: 996. Crossref, Medline, Google Scholar
- 16 : Insulin-like growth factor-I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab2000; 85: 2744. Medline, Google Scholar
- 17 : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Medline, Google Scholar
- 18 : Outcome of sextant biopsy according to gland volume. Urology1997; 49: 55. Crossref, Medline, Google Scholar
- 19 : Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?. Lancet2000; 356: 1902. Crossref, Medline, Google Scholar
- 20 : Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. Eur J Endocrinol2000; 143: 61. Crossref, Medline, Google Scholar
From the Departments of Surgery (Urology Division), Pathology and Medicine, McGill University and Montreal General Hospital Research Institute, Montreal, Quebec, Canada
